

ANAGENICS Limited

ACN 111 304 119

Appendix 4E (ASX Listing Rule 4.3A)

Appendix 4E Preliminary final report

For the financial year ended 30 June 2025

The Appendix 4E of Anagenics Limited and its subsidiaries (ASX: AN1) for the financial year ended 30 June 2025 is filed with the Australian Securities Exchange (ASX) under ASX Listing Rule 4.3A. This report should be read in conjunction with the Anagenics Limited 2025 Annual Report, and any public announcements made during the year by Anagenics Limited in accordance with the continuous disclosure requirements of the *Corporations Act 2001* and ASX Listing Rules.

Information presented for the previous corresponding period is for the financial year ended 30 June 2024.

Results for announcement to the market

Comparison to previous corresponding periods	Increase/ Decrease	%	Amount
Revenue from ordinary activities	Decrease	-52.6	\$5,118,798
Net loss from ordinary activities after tax attributable to shareholders	Decrease	83.5	(\$1,235,675)
Net loss for the period attributable to shareholders	Decrease	83.5	(\$1,235,675)

Refer to the Anagenics Limited 2025 Annual Report for commentary on the above results.

There were no dividends paid, recommended or declared during the current financial period.

There was no change in the gain or loss of control of subsidiaries in the year ended 30 June 2025. None of the subsidiaries applied accounting standards that differ from those used by the Consolidated entity. The Consolidated entity has no interest in associates or joint venture entities.

Net tangible assets per security

Net tangible asset backing per ordinary security

June 2025	June 2024
(0.03) cent	0.09 cent

The net assets include both right-of-use assets and corresponding lease liabilities.

The number of Anagenics shares on issue as at 30 June 2025 was 496.3 million (2024: 461.3 million).

Results commentary

Additional Appendix 4E disclosure requirements can be found in the Anagenics Limited financial report for the year ended 30 June 2025.

This report is based on the consolidated financial statements of Anagenics Limited, which have been audited by William Buck Audit (Vic) Pty Ltd, and they have issued unmodified audit report.

The release of this announcement was authorised by the Board.